Trial Profile
Efficacy and Safety of LY2148568 [exenatide] in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Amylin Pharmaceuticals
- 28 Jun 2011 Results from the long-term extension study were presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2010 Results have been presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
- 25 Jun 2010 Secondary endpoint 'Glycaemic response rate' has been met according to results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.